O'Donovan N - Search Results

1

Identification of pancreatic cancer invasion-related proteins by proteomic analysis.

Walsh N, O'Donovan N, Kennedy S, Henry M, Meleady P, Clynes M, Dowling P. Walsh N, et al. Proteome Sci. 2009 Feb 14;7:3. doi: 10.1186/1477-5956-7-3. Proteome Sci. 2009. PMID: 19216797 Free PMC article.

2

Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays.

O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M. O'Driscoll L, et al. Mol Cancer. 2006 Dec 15;5:74. doi: 10.1186/1476-4598-5-74. Mol Cancer. 2006. PMID: 17173689 Free PMC article.

3

Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.

O'Connor R, Clynes M, Dowling P, O'Donovan N, O'Driscoll L. O'Connor R, et al. Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):805-17. doi: 10.1517/17425255.3.6.805. Expert Opin Drug Metab Toxicol. 2007. PMID: 18028026 Review.

4

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.

Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. Glynn SA, et al. BMC Cancer. 2008 Jan 16;8:9. doi: 10.1186/1471-2407-8-9. BMC Cancer. 2008. PMID: 18199328 Free PMC article.

5

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N. Eustace AJ, et al. J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53. J Transl Med. 2008. PMID: 18823558 Free PMC article.

6

Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells.

Walsh N, Dowling P, O'Donovan N, Henry M, Meleady P, Clynes M. Walsh N, et al. J Proteomics. 2008 Dec 2;71(5):561-71. doi: 10.1016/j.jprot.2008.09.002. Epub 2008 Sep 25. J Proteomics. 2008. PMID: 18848913

7

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.

Corkery B, Crown J, Clynes M, O'Donovan N. Corkery B, et al. Ann Oncol. 2009 May;20(5):862-7. doi: 10.1093/annonc/mdn710. Epub 2009 Jan 15. Ann Oncol. 2009. PMID: 19150933 Free article.

8

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, Clynes M, O'Connor R. Collins DM, et al. Invest New Drugs. 2010 Aug;28(4):433-44. doi: 10.1007/s10637-009-9266-0. Epub 2009 Jun 5. Invest New Drugs. 2010. PMID: 19499189

9

Alterations in integrin expression modulates invasion of pancreatic cancer cells.

Walsh N, Clynes M, Crown J, O'Donovan N. Walsh N, et al. J Exp Clin Cancer Res. 2009 Oct 13;28(1):140. doi: 10.1186/1756-9966-28-140. J Exp Clin Cancer Res. 2009. PMID: 19825166 Free PMC article.

10

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.

Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Browne BC, et al. Ann Oncol. 2011 Jan;22(1):68-73. doi: 10.1093/annonc/mdq349. Epub 2010 Jul 20. Ann Oncol. 2011. PMID: 20647220 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters